An oncologist can stay up to date on new cancer drug approvals without reading journals for hours each day. A scheduled AI research report, sent straight to their inbox, does the searching for them.
Meet Dr. Priya, Oncologist
Dr. Priya treats cancer patients at a busy hospital. Her days are packed: ward rounds, consultations, paperwork. She barely has time to eat lunch, let alone read the FDA's approval announcements, scan clinical trial results, and follow pharma company press releases.
But her job depends on knowing what's new. A drug approved last month might be exactly right for a patient she sees today. Missing that information is not just inconvenient. It could affect patient care.
She used to spend Sunday evenings going through PubMed, the FDA website, and a handful of oncology newsletters. It took two hours every week, and she still felt like she was falling behind.
The Problem With Doing It Manually
Cancer drug news moves fast. The FDA can approve a new therapy on a Tuesday. A trial result drops on a Wednesday. A new indication for an existing drug gets announced on a Friday.
No single website covers all of it. You have to check multiple sources, every few days, just to feel reasonably caught up. For a working clinician, that is simply not realistic.
How Dr. Priya Set Up Her AIDular Report
Dr. Priya signed up for AIDular at aidular.com and set up a weekly report using plain English. No coding, no complex settings.
Here is almost exactly what she typed as her research prompt:
"Every week, find me the latest news on FDA cancer drug approvals, new oncology clinical trial results (especially Phase 3), and any major updates on immunotherapy or targeted therapy treatments. Include the drug name, the cancer type it treats, and a link to the source."
She picked weekly delivery, every Monday morning. Now, before her first patient of the week, she has a clean email in her inbox with sourced summaries of everything that moved in oncology over the past seven days.
What the Report Looks Like
The email AIDular sends her covers things like:
- A new FDA approval for a KRAS-targeted therapy in non-small cell lung cancer
- Updated Phase 3 results for a combination immunotherapy trial in melanoma
- A label expansion for a CDK4/6 inhibitor now covering a new breast cancer subtype
Each item has a short summary and a link to the original source, whether that is the FDA website, a journal like The Lancet Oncology, or a pharma company announcement.
She reads it in about ten minutes. Then she moves on with her week, knowing she has not missed anything significant.
Why This Actually Helps Patients
When Dr. Priya sees a patient whose earlier treatment has stopped working, she now comes to that conversation better prepared. She might already know about a newly approved second-line option she can discuss. That knowledge gap used to close slowly. Now it closes every Monday.
It also helps her prepare for tumor board meetings, where staying current is expected. She is not scrambling to look things up the night before.
Try It Free
If you work in healthcare and feel like the research is always running ahead of you, a scheduled report is one of the simplest fixes out there. AIDular's Lite plan is free. You set it up once, and the information comes to you.
You can get started at aidular.com. No technical knowledge needed.